Overview: Epstein-Barr Early Antigen IgG (EBV EA IgG) TestIntroduction: The Epstein-Barr Early Antigen IgG Test detects IgG antibodies to Epstein-Barr virus early antigen, indicating active or recent infection causing fatigue. Following 2023 IDSA guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, management, and improving outcomes in virology for patients with suspected EBV infections.
Other Names: EBV Early Antigen IgG Assay, EBV EA Antibody Test.
FDA Status: Laboratory-developed test (LDT), meeting virology standards for diagnostic accuracy.
Historical Milestone: EBV antibody testing began in the 1960s with infectious mononucleosis research. EA IgG assays emerged in the 1980s, and by the 2000s, high-sensitivity immunoassays improved accuracy.
Purpose: Diagnoses active or recent EBV infection, guides management, and monitors antibody presence in patients with fatigue.
Test Parameters: 1. EBV Early Antigen IgG
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like fatigue, and list history of EBV-related conditions.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue or history of EBV-related conditions (e.g., mononucleosis). Include current medications or recent infections.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for supportive care.
Procedural Considerations: Uses an immunoassay to detect EBV EA IgG antibodies. Results are available in 3-5 days, enabling clinical decisions.
Factors Affecting Result Accuracy: Cross-reactivity with other viruses may cause false positives. Early or resolved infection may affect results.
Clinical Significance: Positive EA IgG results suggest active or recent EBV infection, guiding management. Negative results may require PCR or VCA IgM testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation.
Additional Supporting Tests: EBV VCA IgG/IgM, EBV PCR, or lymphocyte count to confirm infection status.
Test Limitations: False positives may occur with related viruses. Results require clinical correlation.
References: IDSA EBV Guidelines, 2023; Clinical Infectious Diseases, Cohen JI, 2022.
